RT Journal Article
T1 Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I
A1 Cuesta Martínez, Ángel
A1 Suárez Porto, Eduardo
A1 Larsen, Martin
A1 Jensen, Kim Bak
A1 Sanz, Laura
A1 Compte Grau, Marta
A1 Kristensen, Peter
A1 Álvarez‐Vallina, Luis
AB Although DNA‐based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour‐bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune‐activating genes to the tumour antigen sequence. In this work, we converted a model non‐immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen‐specific T helper 1‐type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene‐mediated immune response and may thus provide a strategy for improving its therapeutic effect.
PB Wiley
SN 0019-2805
YR 2006
FD 2006-02-16
LK https://hdl.handle.net/20.500.14352/101153
UL https://hdl.handle.net/20.500.14352/101153
LA eng
NO Cuesta AM, Suárez E, Larsen M, et al. Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology. 2006;117(4):502-506. doi:10.1111/j.1365-2567.2006.02325.x
NO Fondo de Investigaciones Sanitarias
NO Comunidad de Madrid
NO European Commission
NO Danish Technical Research Council
NO Novo Nordisk Foundation
NO NEMOD Immunotherpies AG
DS Docta Complutense
RD 20 ago 2024